S&P 500 gains to extend record run, set for positive week
Immuneering Corp (NASDAQ:IMRX) Chief Business Officer Harold Eugene Brakewood reported purchasing 1,900 shares of Class A Common Stock on June 20, 2025, at a price of $2.5285, for a total transaction value of $4804. The purchase comes as the stock shows strong momentum, with a 34% gain over the past week and trading at $2.44, well above its 52-week low of $1.00. Following the transaction, Brakewood directly owns 5,800 shares of Immuneering. The $88 million market cap company maintains a strong balance sheet with more cash than debt, and according to InvestingPro analysis, the stock appears undervalued based on its Fair Value estimate. InvestingPro subscribers have access to 11 additional key insights about IMRX’s financial health and growth prospects.
In other recent news, Immuneering Corporation has announced promising results from its Phase 2a clinical trial for atebimetinib, a drug aimed at treating first-line pancreatic cancer. The trial demonstrated a 94% overall survival rate and a 72% progression-free survival rate at six months, surpassing standard care benchmarks. Mizuho (NYSE:MFG) has responded to these positive results by raising its price target for Immuneering to $10 from $8, maintaining an Outperform rating. The firm described the drug as having a favorable safety profile and increased its probability of success assumption to 50%.
In addition to the clinical advancements, Immuneering has increased the target enrollment for the trial and plans to initiate a pivotal trial in 2026. The company recently held its Annual Meeting of Stockholders, where three Class I directors were elected and the appointment of RSM US LLP as the independent accounting firm was ratified. These developments highlight Immuneering’s ongoing efforts to advance its cancer treatment pipeline while maintaining solid corporate governance.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.